<DOC>
	<DOCNO>NCT00334646</DOCNO>
	<brief_summary>This study design evaluate potential pharmacokinetic interaction oral GW679769 IV ( intravenous ) cyclophosphamide administer cancer patient .</brief_summary>
	<brief_title>Cyclophosphamide Drug Interaction Study In Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis cancer . Undergoing chemotherapy cyclophosphamide regimen cyclophosphamide dose 500 700 mg/m2 cycle duration 1428 day . Adequate hematologic , renal hepatic function . Pregnant lactating . CNS ( central nervous system ) metastases . Active systemic infection poorly control medical condition . Patients take CYP3A4 inhibitor within 7 day study treatment CYP3A4 inducer within 48 day study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>cyclophosphamide</keyword>
	<keyword>CINV</keyword>
	<keyword>Chemotherapy induce nausea vomiting</keyword>
</DOC>